UPDATE: BMO Capital Downgrades Akcea Therapeutics, Inc. (AKCA) to Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to UPDATE: BMO Capital Downgrades Akcea Therapeutics, Inc. (AKCA) to Market Perform

Wells Fargo Downgrades Akcea Therapeutics, Inc. (AKCA) to Equal Weight, Following Acquisition

August 31, 2020 11:38 AM EDT

Wells Fargo analyst Jim Birchenough downgraded Akcea Therapeutics, Inc. (NASDAQ: AKCA) from Overweight to Equal Weight.

For an analyst ratings summary and ratings history on Akcea Therapeutics, Inc. click here. For more ratings news on Akcea Therapeutics, Inc. click here.

Shares of Akcea Therapeutics, Inc. closed at $11.38 yesterday.

... More

Pre-Open Stock Movers 8/31: (AIMT) (AKCA) (GNW) (ACST) (LPCN) (BIGC) (More...)

August 31, 2020 8:53 AM EDT

Today's Pre-Open Stock Movers

Aimmune Therapeutics (NASDAQ: AIMT) +172%; Under the terms of the merger agreement, Nestle S.A.'s wholly-owned subsidiary will commence a cash tender offer to acquire all outstanding shares of Aimmune common stock that are not already owned by NHSc for USD34.50 per share in cash, representing a total enterprise value, including the shares of Aimmune held by NHSc, of approximately USD2.6 billion. The USD34.50 per share acquisition price represents a 174% premium to Aimmune's closing share price on August 28, 2020 of USD12.60.


Akcea Therapeutics (NASDAQ:... More

Ionis Pharmaceuticals (IONS) to acquire remaining stake in Akcea Therapeutics (AKCA) for $18.15/sh

August 31, 2020 7:21 AM EDT

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24%, for $18.15 per share in cash. This corresponds to a total transaction value of approximately $500 million on a fully diluted basis. The transaction has been approved by the Ionis and Akcea Boards of Directors, and by the independent Affiliate Transactions Committee of Akcea's Board of... More

Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Highlight Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx))

August 31, 2020 6:01 AM EDT

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) in an online Late Breaking Clinical Trial Session at the ESC Congress 2020, the annual meeting for the European Society of Cardiology.

Vupanorsen is an investigational antisense therapy being developed to treat patients with certain cardiovascular diseases. In the Phase 2 study, vupanorsen met the primary endpoint of... More

Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Present Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx)

August 31, 2020 6:00 AM EDT

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data today from the Phase 2 study of AKCEA-APOCIII-LRx in an online Late Breaking Clinical Trial Session at the ESC Congress 2020, the annual meeting of the European Society of Cardiology.

Results showed that AKCEA-APOCIII-LRx met primary and key secondary endpoints with significant reductions in triglyceride (TG) and apoC-III levels, and a favorable safety and tolerability profile in the treatment of patients with hypertriglyceridemia who have established cardiovascular... More